Form 4: Krystal Biotech Executive Suma Krishnan Sells Shares Under 10b5-1 Trading Plan

Suma Krishnan, President of R&D at Krystal Biotech, sold shares of the company's common stock on December 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Suma Krishnan, President of R&D at Krystal Biotech, executed multiple sales of common stock on December 13, 2024.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2024.
• The trading plan started on September 12, 2024, and will terminate on September 13, 2025, with a limit price of $150.00 per share.
• The plan contemplates quarterly sales of 25,000 shares of common stock.
• The sales were executed at various prices, with weighted average prices ranging from $163.0435 to $171.6245.
• Suma Krishnan also reported sales of shares held by her spouse, Krish S. Krishnan, under a similar 10b5-1 trading plan.
• The spouse's sales were executed at weighted average prices ranging from $163.069 to $171.6288.
• The total number of shares sold by Suma Krishnan directly was 24,377.
• The total number of shares sold by Suma Krishnan's spouse was 24,708.
• After these transactions, Suma Krishnan directly owns 1,475,882 shares and indirectly owns 140,000 shares through trusts.
• After these transactions, Suma Krishnan's spouse indirectly owns 1,537,262 shares.

Sentiment

Score: 5

Explanation: The document reflects routine insider sales under a pre-arranged plan, which is neither positive nor negative. The sentiment is neutral.

Risks

• The sales by a key executive and their spouse could be perceived negatively by the market, potentially impacting the stock price.
• The ongoing sales under the 10b5-1 plan could create continued selling pressure on the stock.

Future Outlook

The 10b5-1 trading plans will continue to execute quarterly sales of 25,000 shares until September 13, 2025, subject to a limit price of $150.00 per share.

Industry Context

This is a routine filing for insider transactions under SEC regulations. The use of 10b5-1 plans is common for executives to manage their stock sales while avoiding accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without violating insider trading laws.
• The reported sales are consistent with typical executive stock sales, where a predetermined plan is used to avoid market timing issues.
• Comparable companies often have similar filings when executives sell shares, such as those seen with executives at companies like Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX).

Related Party Transactions

• The sales by Suma Krishnan's spouse, Krish S. Krishnan, are considered related party transactions.

Stakeholder Impact

• Shareholders may react to the insider sales, potentially impacting the stock price.
• The ongoing sales under the 10b5-1 plan could create continued selling pressure on the stock.

Next Steps

• The 10b5-1 trading plans will continue to execute quarterly sales until September 13, 2025.

Key Dates

Keywords

Krystal Biotech, KRYS, Suma Krishnan, insider trading, 10b5-1 trading plan, stock sale, executive, share sale, beneficial ownership